You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B(06185.HK):重組新冠疫苗(5型腺病毒載體)在阿根廷獲推薦作為加強接種和額外接種的異源疫苗

格隆匯11月15日丨康希諾生物-B(06185.HK)發佈公吿,重組新型冠狀病毒疫苗(5型腺病毒載體)(商品名稱為克威莎)的異源初免-加強的序貫免疫程序獲阿根廷衞生部在其官網推薦,可用於(a)完成初次免疫程序至少6個月後的加強接種程序,適用於醫療衞生工作者和70歲及以上人羣;及(b)完成初次免疫程序至少1個月後的額外接種程序,適用於免疫功能低下的人羣和50歲及以上接受過滅活疫苗初次免疫程序的人羣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account